42 CFR Part 11

What 42 CFR Part 11 is

42 CFR Part 11 is the HHS regulation that gives binding legal force to the ClinicalTrials.gov registration and results-reporting mandate created by Section 801 of the FDA Amendments Act of 2007 (FDAAA 801). Effective 18 January 2017, it defines who must register a trial, what data to submit, and the deadlines and penalties for noncompliance.

For the broader landscape this regulation sits inside — how it relates to ICMJE’s journal-based registration policy and NIH’s separate funding-based reporting policy — see CASRAI’s Clinical Trial Registration and Reporting Compliance guide, which covers the three-way distinction between these overlapping-but-not-identical obligations in full. This term focuses specifically on what 42 CFR Part 11 itself requires as a matter of regulatory text.

Who is bound by it: "applicable clinical trial" and "responsible party"

Part 11 applies only to an "applicable clinical trial" (ACT) — a narrower category than what ICMJE or NIH’s own policy may require registered. An ACT is generally a controlled clinical investigation of a drug or biologic other than a Phase 1 trial, or certain applicable device trials (including required pediatric postmarket device surveillance studies). Phase 1 drug trials are explicitly excluded from the ACT definition, even though the same trial might still need registering to satisfy a journal’s ICMJE-based policy or NIH’s own broader dissemination policy for NIH-funded trials.

Every ACT must have a responsible party — the entity legally accountable for registering the trial and submitting its results. Under 42 CFR 11.10, the responsible party is, by default, the trial’s sponsor. A sponsor may instead designate the trial’s principal investigator as responsible party, but only if the PI meets all of the following: is responsible for conducting the trial, has access to and control over the trial’s data, has the right to publish the trial’s results, and has the actual ability to meet every one of Part 11’s submission requirements. Absent an explicit, qualifying PI designation, the sponsor remains the responsible party by default.

Registration and results-submission deadlines

For an ACT initiated after 27 September 2007, the responsible party must register the trial on ClinicalTrials.gov within 21 days of enrolling the first participant. Required registration data includes descriptive information (title, conditions studied, intervention), recruitment status and eligibility criteria, location and contact information, and administrative data identifying the responsible party and any funding source.

Results information — participant flow, baseline characteristics, prespecified outcome measures and results, and adverse event data — is due no later than 12 months after the trial’s primary completion date (the date the last participant was examined or received an intervention for purposes of final data collection on the trial’s primary outcome). Part 11 permits a certification for a limited extension, up to a maximum of roughly two years past primary completion, in defined circumstances — most commonly when the studied product has not yet been approved, licensed, or cleared by FDA for any use.

Noncompliance and civil monetary penalties

Part 11 gives FDA real enforcement authority, not just a reporting expectation. If FDA determines a responsible party has failed to comply, it can issue a public Notice of Noncompliance, posted directly on the trial’s ClinicalTrials.gov record, which starts a 30-day remediation window. If the violation continues past that window, FDA can pursue civil monetary penalties, with a statutory base of up to $10,000 per day of continued violation (subject to periodic inflation adjustment under federal civil-penalty inflation-adjustment law, so the current enforceable figure may run higher than the original statutory base — confirm the current adjusted amount against FDA’s own civil-penalty guidance before citing a specific current dollar figure). These FDA penalties are separate from, and can stack with, funding-related consequences a federal awarding agency might separately impose on a noncompliant grantee.

Common points of confusion

Two mix-ups come up often enough to flag directly. First, 42 CFR Part 11 is not the same regulation as 21 CFR Part 11 — the latter, in effect since 1997, governs the validity of electronic records and electronic signatures across FDA-regulated processes generally (a completely different subject matter that happens to share the "Part 11" number). Second, 42 CFR Part 11 is narrower than the full universe of registration/reporting obligations a given trial may face: ICMJE’s own registration policy (a condition many journals impose for publication) and NIH’s Policy on the Dissemination of NIH-Funded Clinical Trial Information both use broader definitions than Part 11’s ACT category, and can require registration or results reporting for trials — including some Phase 1 or behavioral studies — that Part 11 itself does not reach. A trial being outside Part 11’s scope does not automatically mean it has no registration or reporting obligation at all.

Related terms

See also ClinicalTrials.gov for the registry system Part 11 governs, and CASRAI’s Clinical Trial Registration and Reporting Compliance guide for how Part 11 fits alongside ICMJE and NIH policy. Sponsors and institutions that outsource the mechanics of registration and results submission often use a dedicated vendor or in-house service — see CASRAI’s Clinical Trial Disclosure Services guide for what that work typically involves.